Karyopharm Therapeutics

Yahoo Finance • 20 days ago

JPMorgan BetaBuilders MSCI U.S. REIT ETF declares quarterly distribution of $0.4053

* JPMorgan BetaBuilders MSCI U.S. REIT ETF (BBRE [https://seekingalpha.com/symbol/BBRE]) - $0.4053 [https://am.jpmorgan.com/us/en/asset-management/adv/products/jpmorgan-betabuilders-msci-us-reit-etf-etf-shares-46641q738]. * 30-Day SEC... Full story

Yahoo Finance • 20 days ago

JPMorgan BetaBuilders International Equity ETF declares quarterly distribution of $0.2556

* JPMorgan BetaBuilders International Equity ETF (BBIN [https://seekingalpha.com/symbol/BBIN]) - $0.2556 [https://am.jpmorgan.com/us/en/asset-management/adv/products/jpmorgan-betabuilders-international-equity-etf-etf-shares-46641q373].... Full story

Yahoo Finance • 5 months ago

Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight

The endometrial cancer market space will experience significant growth during the forecast period of 2025–2034. The future is brighter for patients with endometrial cancer. Targeted agents and biomarker-driven therapies hold promise for im... Full story

Yahoo Finance • 6 months ago

Karyopharm rises on securing $100M in financing to extend cash runway into Q2 2026

Karyopharm Therapeutics (NASDAQ:KPTI [https://seekingalpha.com/symbol/KPTI]) has entered into comprehensive financing and capital structure transactions expected to provide the company with $100 million of financial flexibility and additio... Full story

Yahoo Finance • 7 months ago

Biotech Stocks Surge After Hours: CAPR, TMDX Lead Gains Amid Trial Updates And Earnings Momentum

(RTTNews) - Several biotech and medical technology stocks posted notable gains in after-hours trading on Monday, with momentum driven by a mix of earnings optimism, clinical trial progress, and speculative positioning. While some names ral... Full story

Yahoo Finance • 8 months ago

Top movers analysis in the middle of the day on 2025-08-15: top gainers and losers in today's session.

Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT DFLIW [https://... Full story

Yahoo Finance • 8 months ago

Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026

Earnings Call Insights: Karyopharm Therapeutics Inc. (KPTI) Q2 2025 MANAGEMENT VIEW * Richard A. Paulson, President and CEO, stated that the company is "operating in a period of financial constraints with a near-term debt maturity in O... Full story

Yahoo Finance • 8 months ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Lithium Argentina AG (LAC [https://seekingalpha.com/symbol/LAC]) * Ballard Power Systems (BLDP [https://seekingalpha.com/symbol/BLDP]) * Franco-Nevada Corporation (FNV [ht... Full story

Yahoo Finance • 9 months ago

H.C. Wainwright downgrades Karyopharm stock to Neutral amid financial concerns

Investing.com - H.C. Wainwright downgraded Karyopharm Therapeutics (NASDAQ:KPTI) from Buy to Neutral on Wednesday, removing its price target following the company’s announcement of workforce reductions and financial challenges. According t... Full story

Yahoo Finance • 9 months ago

Karyopharm stock tumbles after disclosing failed financing talks

Investing.com -- Karyopharm Therapeutics Inc (NASDAQ:KPTI) stock plunged 17% after the pharmaceutical company revealed that its efforts to secure additional financing have been unsuccessful so far, raising concerns about its financial stab... Full story

Yahoo Finance • 2 years ago

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

Biomarker Data from Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis (MF) Suggestive of Disease Modification Data Reinforce the Potential for Selinexor in Combination with Ruxolitinib to Become a... Full story

Yahoo Finance • 2 years ago

Karyopharm to Participate at Upcoming Investor Conferences

NEWTON, Mass., Nov. 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participat... Full story

Yahoo Finance • 2 years ago

Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

—  Phase 1b/2 Trial Will Investigate Mezigdomide in Combination with Selinexor  in Patients with Relapsed/Refractory Multiple Myeloma Progressing after T-cell Immunotherapies – — Expected to be Initiated 1H 2024 – NEWTON, Mass., Oct. 30,... Full story

Yahoo Finance • 3 years ago

Karyopharm Therapeutics (KPTI) Q1 2023 Earnings Call Transcript

At this time, I would like to welcome everyone to the Karyopharm Therapeutics first quarter 2023 financial results conference call. Thank you, operator, and thank you all for joining us on today's conference call to discuss Karyopharm's fi... Full story

Yahoo Finance • 4 years ago

Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

– Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication – – Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in May 2022 – NEWTON, Mass.... Full story

Yahoo Finance • 4 years ago

Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

̶  European Commission Decision Anticipated within Approximately 60 Days – NEWTON, Mass. and FLORENCE, Italy, May 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering no... Full story

Yahoo Finance • 4 years ago

Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference

NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participa... Full story

Yahoo Finance • 4 years ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., May 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that in connection with the hiring of Reshma Rangwala, Exe... Full story

Yahoo Finance • 4 years ago

Karyopharm to Participate at the Canaccord Genuity Horizons in Oncology Conference

NEWTON, Mass., April 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participa... Full story